Stoke Therapeutics Inc
STOK25.110USD
+2.740+12.25%
收盤 11/11, 16:00（美東）報價延遲15分鐘
1.38B總市值
34.12本益比TTM
關於 Stoke Therapeutics Inc 公司
Stoke Therapeutics, Inc. 是一家生物技術公司，致力於通過使用基於核糖核酸 (RNA) 的藥物上調蛋白質表達來解決嚴重疾病的根本原因。該公司通過其專有的靶向增強核基因輸出 (TANGO) 方法，致力於開發反義寡核苷酸 (ASO) 以選擇性恢復蛋白質水平。其首款化合物 STK-001 正在進行臨牀試驗，用於治療 Dravet 綜合徵，這是一種嚴重的漸進性遺傳性癲癇。TANGO 旨在通過增加或刺激健康基因的蛋白質輸出來恢復缺失的蛋白質，從而補償無功能的基因副本。該公司正在開發 STK-002，用於治療最常見的遺傳性視神經疾病常染色體顯性視神經萎縮 (ADOA)。該公司的初始重點是單倍體不足以及中樞神經系統和眼睛疾病。
Stoke Therapeutics Inc簡介
公司代碼STOK
公司名稱Stoke Therapeutics Inc
上市日期Jun 19, 2019
CEOMr. Ian F. Smith, CPA
員工數量128
證券類型Ordinary Share
年結日Jun 19
公司地址45 Wiggins Avenue
城市BEDFORD
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編01730
電話17814308200
網址https://www.stoketherapeutics.com/
公司代碼STOK
上市日期Jun 19, 2019
CEOMr. Ian F. Smith, CPA
Stoke Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Prof. Dr. Adrian R. Krainer, Ph.D.
Prof. Dr. Adrian R. Krainer, Ph.D.
Independent Director
Independent Director
404.72K
--
Dr. Edward M. (Ed) Kaye, M.D.
Dr. Edward M. (Ed) Kaye, M.D.
Director
Director
49.12K
-46.36%
Mr. Jonathan Allan, J.D.
Mr. Jonathan Allan, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
4.32K
--
Dr. Barry S. Ticho, M.D., Ph.D.
Dr. Barry S. Ticho, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Arthur A. Levin, Ph.D.
Dr. Arthur A. Levin, Ph.D.
Independent Director
Independent Director
--
--
Ms. Julie Anne Smith
Ms. Julie Anne Smith
Independent Director
Independent Director
--
--
Mr. Thomas Leggett
Mr. Thomas Leggett
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Arthur O. Tzianabos, Ph.D.
Dr. Arthur O. Tzianabos, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Seth L. Harrison, M.D.
Dr. Seth L. Harrison, M.D.
Independent Director
Independent Director
--
--
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Prof. Dr. Adrian R. Krainer, Ph.D.
Prof. Dr. Adrian R. Krainer, Ph.D.
Independent Director
Independent Director
404.72K
--
Dr. Edward M. (Ed) Kaye, M.D.
Dr. Edward M. (Ed) Kaye, M.D.
Director
Director
49.12K
-46.36%
Mr. Jonathan Allan, J.D.
Mr. Jonathan Allan, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
4.32K
--
Dr. Barry S. Ticho, M.D., Ph.D.
Dr. Barry S. Ticho, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Arthur A. Levin, Ph.D.
Dr. Arthur A. Levin, Ph.D.
Independent Director
Independent Director
--
--
Ms. Julie Anne Smith
Ms. Julie Anne Smith
Independent Director
Independent Director
--
--
收入明細
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
暫無數據
地區USD
名稱
營收
佔比
United States
13.82M
0.00%
業務
地區
暫無數據
股東統計
更新時間: 10月8日 週三
更新時間: 10月8日 週三
持股股東
股東類型
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
10.42%
Lynx1 Capital Advisors LLC
9.46%
RTW Investments L.P.
8.97%
Baker Bros. Advisors LP
8.11%
Redmile Group, LLC
7.66%
其他
55.38%
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
10.42%
Lynx1 Capital Advisors LLC
9.46%
RTW Investments L.P.
8.97%
Baker Bros. Advisors LP
8.11%
Redmile Group, LLC
7.66%
其他
55.38%
股東類型
持股股東
佔比
Investment Advisor
49.19%
Investment Advisor/Hedge Fund
38.56%
Research Firm
14.55%
Hedge Fund
12.80%
Individual Investor
4.21%
Pension Fund
0.20%
Bank and Trust
0.20%
Insurance Company
0.03%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
305
65.94M
115.45%
-1.62M
2025Q2
300
63.05M
115.48%
-5.58M
2025Q1
306
66.97M
122.66%
-2.21M
2024Q4
301
61.22M
115.58%
-8.44M
2024Q3
297
61.15M
115.51%
-9.18M
2024Q2
284
64.23M
122.75%
+5.19M
2024Q1
273
57.18M
122.36%
+3.72M
2023Q4
261
48.04M
104.80%
-6.40M
2023Q3
264
46.81M
105.69%
-6.29M
2023Q2
260
49.41M
111.78%
-2.48M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Fidelity Management & Research Company LLC
5.95M
10.86%
+3.48M
+140.94%
Jun 30, 2025
Lynx1 Capital Advisors LLC
5.40M
9.86%
+112.75K
+2.13%
Jun 30, 2025
RTW Investments L.P.
5.12M
9.35%
--
--
Jun 30, 2025
Baker Bros. Advisors LP
4.63M
8.46%
--
--
Jun 30, 2025
Redmile Group, LLC
4.38M
7.99%
-110.05K
-2.45%
Jun 30, 2025
Morgan Stanley & Co. LLC
3.37M
6.16%
+157.85K
+4.91%
Jun 30, 2025
TD Securities, Inc.
3.17M
5.79%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
2.94M
5.36%
+162.06K
+5.84%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.98M
5.44%
+148.82K
+5.26%
Jun 30, 2025
Marshall Wace LLP
2.30M
4.2%
+168.77K
+7.92%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
Innovator IBD 50 Fund ETF
4.85%
WisdomTree BioRevolution Fund
2.15%
First Trust Dow Jones Select MicroCap Index Fund
1.79%
Janus Henderson Small Cap Growth Alpha ETF
1.47%
Virtus LifeSci Biotech Clinical Trials ETF
1.43%
Global X Genomics & Biotechnology ETF
1.14%
Invesco Dorsey Wright Healthcare Momentum ETF
0.77%
ALPS Medical Breakthroughs ETF
0.73%
iShares Health Innovation Active ETF
0.65%
Janus Henderson Small/Mid Cap Growth Alpha ETF
0.64%
查看更多
Innovator IBD 50 Fund ETF
佔比4.85%
WisdomTree BioRevolution Fund
佔比2.15%
First Trust Dow Jones Select MicroCap Index Fund
佔比1.79%
Janus Henderson Small Cap Growth Alpha ETF
佔比1.47%
Virtus LifeSci Biotech Clinical Trials ETF
佔比1.43%
Global X Genomics & Biotechnology ETF
佔比1.14%
Invesco Dorsey Wright Healthcare Momentum ETF
佔比0.77%
ALPS Medical Breakthroughs ETF
佔比0.73%
iShares Health Innovation Active ETF
佔比0.65%
Janus Henderson Small/Mid Cap Growth Alpha ETF
佔比0.64%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
